Shares of Bausch Health Companies Inc. (TSE:BHC - Get Free Report) were down 0.3% during mid-day trading on Thursday . The company traded as low as C$11.33 and last traded at C$11.45. Approximately 141,183 shares were traded during trading, a decline of 62% from the average daily volume of 370,573 shares. The stock had previously closed at C$11.48.
Wall Street Analyst Weigh In
Separately, Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th.
Get Our Latest Analysis on Bausch Health Companies
Bausch Health Companies Stock Down 2.4 %
The business has a 50 day simple moving average of C$11.28 and a 200 day simple moving average of C$9.86. The company has a market capitalization of C$4.10 billion, a price-to-earnings ratio of -6.54, a PEG ratio of 0.21 and a beta of 0.77. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.19 and a quick ratio of 0.58.
Bausch Health Companies (TSE:BHC - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported C$1.53 earnings per share for the quarter, beating the consensus estimate of C$1.43 by C$0.10. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The company had revenue of C$3.42 billion during the quarter, compared to the consensus estimate of C$3.36 billion. As a group, equities analysts predict that Bausch Health Companies Inc. will post 5.5472637 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Bausch Health Companies news, Senior Officer Seana Lynne Carson sold 13,370 shares of Bausch Health Companies stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. 11.28% of the stock is owned by company insiders.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
